Sagimet Biosciences Inc
F:0O2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sagimet Biosciences Inc
F:0O2
|
US |
|
G
|
Goodland Group Ltd
SGX:5PC
|
SG |
|
J
|
JAS Asset PCL
SET:J
|
TH |
|
F
|
First Solar Inc
XMUN:F3A
|
US |
|
P
|
PPL Corp
F:PP9
|
US |
|
Yojee Ltd
F:SRC
|
AU |
Intrinsic Value
Is 0O2 undervalued or overvalued?
See the intrinsic value estimate for 
Sagimet Biosciences Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
0O2 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 0O2’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Sagimet Biosciences Does
Sagimet Biosciences is a drug-development company focused on medicines that block fatty acid synthase, an enzyme tied to fat production in the body. Its lead program is denifanstat, an oral drug candidate being studied for liver disease and severe acne. The company does not sell a broad consumer product line; it develops prescription drug candidates and works to move them through clinical testing and regulatory approval.
- Headquarters
- United States of America US
- Employees
- 16
- IPO date
- Jul 14, 2023
Earnings Waterfall
Sagimet Biosciences Inc
The intrinsic value for Sagimet Biosciences Inc (0O2) under the Base Case is hidden EUR.
Compared with the current market price of 8.62 EUR, the stock appears hidden.